
    
      This is a pilot study to evaluate the safety and efficacy of repeated MSC infusions to
      subjects with OI. This study will evaluate subjects on two separate strata. Stratum A will
      include subjects with a diagnosis of Type II or Type III osteogenesis imperfecta who have
      previously undergone a bone marrow transplant. Stratum A may use previously harvested and
      cryopreserved bone marrow mononuclear cells from original BMT donor or freshly harvested or
      cryopreserved bone marrow mononuclear cells obtained from a haploidentical healthy parent or
      sibling. Stratum B will include subjects with Type II or III osteogenesis imperfecta who have
      not undergone a bone marrow transplant. Stratum B will only receive freshly harvested or
      cryopreserved bone marrow mononuclear cells from a haploidentical healthy parent or sibling.

      Participants will receive MSC infusions approximately every 4 months to complete a total of 6
      infusions over 20 months. Participants will be followed for 12 months post their last MSC
      infusion.
    
  